Show simple item record

dc.creatorLevett, Jeremy Y.
dc.creatorRaparelli, Valeria
dc.creatorMardigyan, Vartan
dc.date.accessioned2020-09-16T19:50:59Z
dc.date.available2020-09-16T19:50:59Z
dc.date.created2020
dc.identifier.issn2589-790Xspa
dc.identifier.otherhttps://doi.org/10.1016/j.cjco.2020.09.003spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/13337
dc.description.abstractThe coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly evolving, with important cardiovascular considerations. The presence of underlying cardiovascular risk factors and established cardiovascular disease (CVD) may affect the severity and clinical management of patients with COVID-19. We conducted a review of the literature to summarize the cardiovascular pathophysiology, risk factors, clinical presentations, and treatment considerations of COVID-19 patients with underlying CVD. The angiotensin-converting enzyme 2 (ACE2) enzyme has been identified as a functional receptor for the SARS-CoV-2 virus, and is associated with the cardiovascular system. Hypertension, diabetes, and CVD are the most common comorbidities in COVID-19 patients, and these factors have been associated with the progression and severity of COVID-19. However, elderly populations, who develop more severe COVID-19 complications, are naturally exposed to these comorbidities, underscoring the possible confounding of age. Observational data supports international cardiovascular societies’ recommendation to not discontinue ACEi/ARB therapy in patients with guideline indications out of fear for the increased risk of SARS-CoV-2 infection, severe disease, or death. In addition to the cardiotoxicity of experimental antivirals and potential interactions of experimental therapies with cardiovascular drugs, several strategies for cardiovascular protection have been recommended in COVID-19 patients with underlying CVD. Troponin elevation is associated with increased risk of in-hospital mortality and adverse outcomes in patients with COVID-19. Cardiovascular care teams should have a high index of suspicion for fulminant myocarditis-like presentations being SARS-CoV-2 positive, and remain vigilant for cardiovascular complications in COVID-19 patients.spa
dc.format.extent36 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherCJC Openspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectSARS-CoV-2spa
dc.subjectCOVID-19spa
dc.subjectCardiovascular systemspa
dc.subjectCardiovascular diseasespa
dc.subjectTreatment considerationsspa
dc.subjectCardiovascular drug interactionsspa
dc.subjectReviewspa
dc.titleCardiovascular pathophysiology, epidemiology, and treatment 2 considerations of coronavirus disease 2019 (covid-19): A revieweng
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttps://doi.org/10.1016/j.cjco.2020.09.003spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record